-
Sector Analysis
NewCell and Gene Therapies in Hemophilia A and B – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies (CGT) in Hemophilia A and B Market Report Overview The hemophilia A and B CGT market reached $12 million in 2023 with massive expansions across therapeutic areas. The CGT in Hemophilia A and B market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in Hemophilia A & B including launch date projections, key clinical trial analysis, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANB-10 in Hemophilia A (Factor VIII Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANB-10 in Hemophilia A (Factor VIII Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANB-10 in Hemophilia A (Factor VIII Deficiency) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levetiracetam ER in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levetiracetam ER in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levetiracetam ER in Mild Cognitive Impairment Drug Details: Levetiracetam ER...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – D3S-001 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - D3S-001 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. D3S-001 in Pancreatic Cancer Drug Details: D3S-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BCD-245 in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCD-245 in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCD-245 in Neuroblastoma Drug Details: BCD-245 is under development for treatment of neuroblastoma....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Divozilimab in Neuromyelitis Optica (Devic’s Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Divozilimab in Neuromyelitis Optica (Devic's Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Divozilimab in Neuromyelitis Optica (Devic's Syndrome) Drug Details: Divozilimab (Ivlizi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Divozilimab in Systemic Sclerosis (Scleroderma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Divozilimab in Systemic Sclerosis (Scleroderma) Drug Details: Divozilimab (Ivlizi) is a monoclonal antibody. It is...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Malignant Pleural Mesothelioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Drugs In Development, 2023’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Spinal Muscular Atrophy (SMA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Muscular Atrophy (SMA) - Drugs In Development, 2023’, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...